Crux, Inc.

Crux, Inc. specializes in facilitating access to affordable healthcare therapies. Founded in McLean, US, in 2024. In November 2025, Crux, Inc.

raised USD 6. 5 million in pre-seed funding led by Red Cell Partners. Crux offers an innovative benefits and lifestyle engagement platform designed to facilitate affordable access to transformative quality-of-life (QoL) therapies. The core product revolves around negotiating directly with pharmaceutical manufacturers to secure significant pricing discounts on popular yet costly medications and treatments that often fall outside conventional insurance coverage.

This approach allows employers of all sizes, from large pharmaceutical companies to smaller organizations, to provide their employees with a streamlined benefit that reduces out-of-pocket expenses for necessary prescriptions. The platform functions by combining employer-funded non-taxed subsidies with employee contributions, ensuring frictionless access to medications at competitive prices. Crux's services are primarily directed toward U. S.

-based employers, positioning itself effectively in the healthcare benefits market to enhance employee health outcomes and talent retention. Crux operates on a transaction structure that eliminates traditional fees and hidden costs associated with healthcare benefits. Revenue is generated through a model where employers pay only for the benefits utilized by their employees, which are facilitated through the platform without any setup or ongoing management fees. Clients can customize their funding contributions to support employee out-of-pocket costs, making it a flexible option for organizations.

While specific pricing details for individual products or services are not disclosed, the model emphasizes a direct relationship between Crux and its clients, focusing on a transparent healthcare purchasing experience. The combination of negotiated medication pricing and employer contributions establishes a straightforward transactional framework that optimizes cost efficiency for both employers and employees. The organization plans to use the November 2025 funding to grow its operations and speed up development of its medication-benefits platform.